Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lankof is a combination pharmaceutical product developed and marketed by Lancet Pharmaceuticals, an Indian branded generic company. It is primarily indicated for the relief of productive cough associated with respiratory conditions such as bronchitis, bronchial asthma, and other bronchospastic disorders. The formulation typically contains four active ingredients: terbutaline, ambroxol, guaifenesin, and menthol. Terbutaline acts as a selective beta-2 adrenergic agonist, providing bronchodilation by relaxing the smooth muscles of the airways. Ambroxol serves as a mucolytic agent that thins and loosens mucus, facilitating its clearance from the respiratory tract. Guaifenesin is an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi. Menthol is included for its soothing properties and its ability to provide a cooling sensation in the throat, which helps alleviate irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lankof.